Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation

Out of the breast cancer subtypes, triple-negative breast cancer (TNBC) has the poorest prognosis without effective targeted therapies. Metformin, a first-line drug for type 2 diabetes mellitus, was demonstrated to target breast cancer stem cells selectively. However, the efficiency and the mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Peiguo, Liu, Wenjing, Tala, Wang, Haixia, Li, Fubing, Zhang, Hailin, Wu, Yingying, Kong, Yanjie, Zhou, Zhongmei, Wang, Chunyan, Chen, Wenlin, Liu, Rong, Chen, Ceshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396048/
https://www.ncbi.nlm.nih.gov/pubmed/28480051
http://dx.doi.org/10.1038/celldisc.2017.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396048/
https://www.ncbi.nlm.nih.gov/pubmed/28480051
http://dx.doi.org/10.1038/celldisc.2017.10

Ejemplares similares